PT  - JOURNAL ARTICLE
AU  - Sherwin DeSouza
AU  - Dana Angelini
TI  - Updated guidelines for immune thrombocytopenic purpura: Expanded management options
AID  - 10.3949/ccjm.88a.20201
DP  - 2021 Dec 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 664--668
VI  - 88
IP  - 12
4099  - http://www.ccjm.org/content/88/12/664.short
4100  - http://www.ccjm.org/content/88/12/664.full
SO  - Cleve Clin J Med2021 Dec 01; 88
AB  - The current American Society of Hematology (ASH) guidelines for the management of patients with immune thrombocytopenic purpura (ITP) are an update to the 2011 guidelines. The updates focus on treating patients with ITP without bleeding in both outpatient and inpatient settings, including those with newly diagnosed, persistent, and chronic ITP refractory to first-line therapy. Recommendations for therapy include corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin-receptor agonists, as well as observation.